Up .35 - 20% in premarket on positive news.
7:17AM Generex Biotech says clinical trial results from cancer vaccine show that vaccine is safe, well-tolerated (GNBT) 1.75 : Co announces the results of clinical studies on a novel cancer vaccine being developed by its wholly owned immunotherapeutics subsidiary, Antigen Express, will be presented at the Annual San Antonio Breast Cancer Symposium. Co says the trials have shown that the vaccine is safe, well-tolerated and produces a significant immune response in breast cancer patients. While the target of AE37 is the same as that of the marketed cancer drug Herceptin, co says the activity of AE37 relies on its ability to stimulate a patient's own immune system to recognize the cancer target rather than by interacting with the target directly. They say the advantage of this is that the immune system, once activated, is capable of detecting lower levels of the target protein than is Herceptin and that the anti-tumor activity lasts long after termination of AE37 treatment.
7:17AM Generex Biotech says clinical trial results from cancer vaccine show that vaccine is safe, well-tolerated (GNBT) 1.75 : Co announces the results of clinical studies on a novel cancer vaccine being developed by its wholly owned immunotherapeutics subsidiary, Antigen Express, will be presented at the Annual San Antonio Breast Cancer Symposium. Co says the trials have shown that the vaccine is safe, well-tolerated and produces a significant immune response in breast cancer patients. While the target of AE37 is the same as that of the marketed cancer drug Herceptin, co says the activity of AE37 relies on its ability to stimulate a patient's own immune system to recognize the cancer target rather than by interacting with the target directly. They say the advantage of this is that the immune system, once activated, is capable of detecting lower levels of the target protein than is Herceptin and that the anti-tumor activity lasts long after termination of AE37 treatment.
